Key result
Elevated ANGPTL8 strongly predicts 10-year human mortality, while Angptl8 deletion extends lifespan in mice.
Why the study?
Endocrine regulators promoting adipose tissue senescence remain poorly defined, and the direct role of ANGPTL8 in adipose senescence and organismal aging is unclear.
ANGPTL8 is a key endocrine regulator of adipose tissue senescence and systemic aging, and its inhibition may represent a therapeutic target for delaying age-associated functional decline.
Answers are grounded in this paper and cite their sources.
Positions ANGPTL8 inhibition as a novel anti-aging strategy; leaves open clinical translation pending human trials.
Adipose tissue senescence is increasingly recognized as a key driver of systemic aging and age-related functional decline, yet the endocrine regulators that actively promote this process remain poorly defined. Angiopoietin-like protein 8 (ANGPTL8) is a metabolic factor implicated in lipid metabolism and inflammation and has been associated with multiple aging-related disorders. However, its direct role in adipose tissue senescence and organismal aging remains unclear. Here, we identify ANGPTL8 as a previously unrecognized regulator of adipose tissue aging through integrative analyzes of human cohorts, animal models, transcriptomics, and cellular studies. In a large human cohort, circulating ANGPTL8 levels were strongly associated with biological aging and mortality risk and significantly improved machine learning-based models for age and survival prediction. Consistent with these findings, genetic deletion of Angptl8 in mice extended lifespan, attenuated aging-associated functional decline, and reduced senescence markers in adipose tissue. Transcriptomic analyzes revealed age-dependent upregulation of ANGPTL8 in adipocytes accompanied by activation of pro-senescent transcriptional programs. Mechanistically, ANGPTL8 directly interacted with AKT2 and activated the AKT-mTOR-S6K signaling pathway, thereby promoting cell-autonomous adipocyte senescence. Genetic or pharmacological inhibition of this pathway abolished the pro-senescent effects of ANGPTL8. Collectively, our findings identify ANGPTL8 as an endocrine regulator linking metabolic dysfunction to adipose tissue senescence and systemic aging, highlighting the ANGPTL8-AKT2-mTOR axis as a potential therapeutic target for delaying age-associated functional decline.
No takes yet. Share an insight, caveat, or question.
He et al. (2026) studied Aging and mortality. ANGPTL8 vs. Low ANGPTL8 levels / Wild-type was evaluated on 10-year all-cause mortality prediction and biological age estimation. Elevated circulating ANGPTL8 levels strongly predicted biological aging and 10-year mortality in humans, while genetic deletion of Angptl8 in mice extended lifespan and attenuated age-related functional decline.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: